ArticleViruses2025
Cytomegalovirus Seroprevalence in Northern Poland in the Population Planning Pregnancy and Pregnant Women.
Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Long-term dynamics of cytomegalovirus-specific antibodies in a longitudinal cohort of children followed up for the first decade of life.Scientific reports · 2025Article
- Prevalence of Cytomegalovirus Antibodies in Croatian Childbearing-Aged and Pregnant Women: A Ten-Year Retrospective Study (2015-2024).Pathogens (Basel, Switzerland) · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus is an enveloped DNA virus. All forms of CMV infection-primary infection, reactivation, and infection with a different strain-may be asymptomatic. The risk of vertical transmission in the periconceptional period is approximately 20%, the risk of primary infection in the first trimester is approximately 30%, and in the third trimester the risk increases to 70%. However, the most severe forms of congenital cytomegaly in newborns are related to infections in the periconceptional period. Offering a vaccine to the seronegative patients planning pregnancy may decrease incidents of congenital cytomegaly in neonates. The authors performed retrospective analysis of seroprevalence of CMV in 909 women who reported for pre-conceptional visits or routine pregnancy follow-ups (2003-2023). In the analyzed group, 577 (63.7%) women were seropositive. No influence related to the women's age and place of residence was found. Higher seroprevalence was observed in women with children or those working in contact with many people. In the group of 332 seronegative patients, 21 (0.6%) were diagnosed with primary infection during pregnancy. Vaccinating 36.3% of patients planning pregnancy could significantly decrease the risk of primary infection during pregnancy, vertical transmission of CMV, and symptomatic infection in the neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.